Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for kerx
15.35
+0.08 (0.52%)
After Hours: 15.30 -0.05 (-0.33%)
Jul 30, 7:23PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.27 - 15.80
52 week 8.29 - 17.46
Open 15.45
Vol / Avg. 1.09M/1.50M
Mkt cap 1.40B
P/E     -
Div/yield     -
EPS -0.70
Shares 91.45M
Beta 3.22
Inst. own 83%
Jul 30, 2014
Q2 2014 Keryx Biopharmaceuticals, Inc. Earnings Release (Estimated)
Jun 24, 2014
Keryx Biopharmaceuticals Inc at JMP Securities Healthcare Conference - Webcast
Jun 23, 2014
Keryx Biopharmaceuticals, Inc. 2014 Annual Shareholder Meeting
Jun 12, 2014
Keryx Biopharmaceuticals Inc at Goldman Sachs Healthcare Conference - Webcast
May 8, 2014
Q1 2014 Keryx Biopharmaceuticals, Inc. Earnings Release
May 8, 2014
Q1 2014 Keryx Biopharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -135.30% -667.60%
Operating margin -136.51% -672.61%
EBITD margin - -671.84%
Return on average assets -49.09% -117.81%
Return on average equity -57.33% -167.22%
Employees 41 -
CDP Score - -

Address

750 LEXINGTON AVENUE
NEW YORK, NY 10022
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Keryx Biopharmaceuticals, Inc. (Keryx) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease. The Company is developing KRX-0502, an investigational, ferric citrate, oral compound that binds to phosphate. Under the name Zerenex, KRX-0502 has completed a United States-based Phase III clinical program for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Ron Bentsur Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
James F. Oliviero III Chief Financial Officer, Treasurer, Corporate Secretary
Age: 38
Bio & Compensation  - Reuters
Gregory P. Madison Chief Operating Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Bio & Compensation  - Reuters
Thomas M. Edwards Vice President - US Sales
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
Daniel W. Olmstead Vice President - Payer Access
Bio & Compensation  - Reuters
Amit Sharma M.D. Vice President - Medical Affairs
Bio & Compensation  - Reuters
Amy B. Sullivan Vice President - Corporate Development and Public Affairs
Bio & Compensation  - Reuters